Global Associations between UVR Exposure and Current Eczema Prevalence in Children from ISAAC Phase Three

and the, ISAAC Phase Three Study Group

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

We sought to examine the relationship globally between UVR dose exposure and current eczema prevalences. ISAAC Phase Three provided data on eczema prevalence for 13- to 14-year-olds in 214 centers in 87 countries and for 6- to 7-year-olds in 132 centers in 57 countries. Linear and nonlinear associations between (natural log transformed) eczema prevalence and the mean, maximum, minimum, standard deviation, and range of monthly UV dose exposures were assessed using linear mixed-effects regression models. For the 13- to 14-year-olds, the country-level eczema prevalence was positively and linearly associated with country-level monthly mean (prevalence ratio = 1.31 [95% confidence interval = 1.05–1.63] per kJ/m2) and minimum (1.25 [1.06–1.47] per kJ/m2) UVR dose exposure. Linear and nonlinear associations were also observed for other metrics of UV. Results were similar in trend, but nonsignificant, for the fewer centers with 6- to 7-year-olds (e.g., 1.24 [0.96–1.59] per kJ/m2 for country-level monthly mean UVR). No consistent within-country associations were observed (e.g., 1.05 [0.89–1.23] and 0.92 [0.71–1.18] per kJ/m2 for center-level monthly mean UVR for the 13- to 14- and 6- to 7-year-olds, respectively). These ecological results support a role for UVR exposure in explaining some of the variation in global childhood eczema prevalence.

Original languageEnglish (US)
Pages (from-to)1248-1256
Number of pages9
JournalJournal of Investigative Dermatology
Volume137
Issue number6
DOIs
StatePublished - Jun 2017

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Dermatology
  • Cell Biology

Fingerprint Dive into the research topics of 'Global Associations between UVR Exposure and Current Eczema Prevalence in Children from ISAAC Phase Three'. Together they form a unique fingerprint.

  • Cite this